◇ Compound Reference
Tuftsin Analog · 10mg
Synthetic heptapeptide. Modulates the HPA axis and GABAergic system - anxiolytic effect without sedation or dependence risk.
Tuftsin Analog · 10mg per vial · dispensed after a physician review.
Selank is a 7-amino-acid synthetic peptide derived from the immunomodulatory peptide tuftsin. Approved in Russia for anxiety disorders.
Demonstrates anxiolytic activity without sedation, dependence, or cognitive impairment.
Modulates GABAergic and serotonergic systems. Increases enkephalin levels and modulates HPA axis activity.
Anti-inflammatory and immunomodulatory effects also documented.
Nootropic / neuro - Semax, Selank, DSIP, Oxytocin, PT-141, Kisspeptin
These protocols target cognition, mood, stress regulation, and sleep. Their effects are mostly subjective and behavioral, so monitoring leans on functional and stress-axis markers more than a classic blood panel - the aim is to confirm benefit without disrupting your stress hormones or sleep architecture.
Incremental approach. These are low-dose, often short-course or as-needed protocols. Vivre tracks how you actually feel and function alongside a light marker panel, rather than chasing numbers - the subjective response is the primary signal here.
Educational only - not medical advice or a dosing instruction. Your physician orders the tests, sets your dose, interprets results, and decides if a protocol is right for you. See the Informed Consent & Disclaimer for full terms.
| Class | Synthetic tuftsin analogue heptapeptide |
| Studied mechanism | Anxiolytic/immunomodulatory; GABA/monoamine-related effects in regional literature |
| Human pharmacokinetics | Short peptide half-life; intranasal use studied |
| Evidence base | Moderate within regional literature; limited Western controlled trials |
| Form | Lyophilized powder / intranasal, under clinical protocol |
| Regulatory status | Not an approved therapy in most markets; physician-supervised use only |
Original Russian publication describing Selank as a synthetic tuftsin analogue developed at the Russian Academy of Sciences. Preclinical anxiolytic activity and reported nootropic effects in rodent models. Important methodology notes: publication is in Russian; controlled trials in Western peer-reviewed literature are not available. Selank is registered in Russia for generalised anxiety disorder but not approved in the US, EU, or Asia-Pacific markets.
View on publisher ↗Subsequent reviews summarise Selank's proposed mechanism (modulation of GABAergic and serotonergic systems, interferon-gamma stabilisation) and a small set of Russian clinical reports in generalised anxiety. The evidence base is predominantly Russian-language, with limited independent Western replication. No major-journal RCT for anxiety, cognition, or any other endpoint has been published in Western peer-reviewed literature.
View on publisher ↗Preclinical real-time PCR transcriptomic study in rats. Selank administration modulated expression of multiple genes involved in GABAergic neurotransmission - including GABA-A receptor subunits, GAT-1/GAT-3 transporters, and ion-channel-related genes - within hours of dosing. Establishes a molecular basis for Selank's reported anxiolytic effect via GABAergic modulation rather than direct receptor agonism. Findings are preclinical (rat brain tissue), not human outcomes - but the study is published in a Western-indexed peer-reviewed journal, which strengthens the mechanistic evidence relative to the predominantly Russian-language clinical literature.
View on publisher ↗Preclinical rat study using the unpredictable chronic mild stress (UCMS) model - a validated paradigm for stress-induced anxiety and depressive behaviours. Co-administration of Selank with diazepam reduced anxiety indicators back toward baseline more effectively than either compound alone, suggesting a non-overlapping mechanism complementary to benzodiazepine GABA-A potentiation. Important framing: preclinical model only. Combination is not approved or studied in humans. The interest of the study for Vivre is the mechanistic hypothesis it supports - that Selank acts as an allosteric/transcriptomic modulator rather than a direct benzodiazepine-like agonist.
View on publisher ↗Selank is verified and lot-tested, dispensed following a Biological Audit. The Audit is complimentary for the Batch 001 cohort.
Are you 18 years of age or older?